-
1Academic Journal
Συγγραφείς: A. A. Zagidullina, O. A. Kuznetsova, M. Yu. Fedyanin, Z. Z. Mamedli, V. A. Aliev, A. V. Polynovskiy, O. A. Malikhova, I. A. Karasev, A. M. Stroganova, A. A. Tryakin, А. А. Загидуллина, О. А. Кузнецова, М. Ю. Федянин, З. З. Мамедли, В. А. Алиев, А. В. Полыновский, О. А. Малихова, И. А. Карасев, А. М. Строганова, А. А. Трякин
Συνεισφορές: The article was prepared without sponsorship, Статья подготовлена без спонсорской поддержки
Πηγή: Malignant tumours; Том 14, № 2 (2024); 19-28 ; Злокачественные опухоли; Том 14, № 2 (2024); 19-28 ; 2587-6813 ; 2224-5057
Θεματικοί όροι: неоаъювантное лечение, immunotherapy, prolgolimab, microsatellite instability, neoadjuvant treatment, иммунотерапия, пролголимаб, микросателлитная нестабильность
Περιγραφή αρχείου: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/1327/941; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Sung H., Ferlay J., Siegel R.L., et al. Global сancer ыtatistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–249. doi:10.3322/caac.21660; Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69(1):7–34. doi:10.3322/caac.21551; Jensen L.H., Kjaer M.L., Larsen F.O., et al. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J Clinical Oncol 2023;41(17):LBA3503-LBA3503(2023). doi:10.1200/JCO.2023.41.17_suppl.LBA3503; Федянин М.Ю., Гладков О.А., Гордеев С.С. и соавт. Практические рекомендации по лекарственному лечению рака ободочной кишки, ректосигмоидного соединения и прямой кишки. Злокачественные опухоли 2023;13(3s2):425–482. doi:10.18027/2224-5057-2023-13-3s2-1-425-482.; Zhang X., Wu T., Cai X., et al. Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities. Front Immunol 2022;13:795972. doi:10.3389/fimmu.2022.795972; Трякин А.А., Федянин М.Ю., Цуканов А.С. и соавт. Микросателлитная нестабильность как уникальная характеристика опухолей и предиктор эффективности иммунотерапии. Злокачественные опухоли. 2019;9(4):59–69. doi:10.18027/2224-5057-2019-9-4-59-69.; Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol 2012;13(11):1152–1160. doi:10.1016/S1470-2045(12)70348-0; Cercek A., Fernandes G.D.S., Roxburgh C.S., et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res 2020;26(13):3271–3279. doi:10.1158/1078-0432.CCR-19-3728; Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019;38(1):255. doi:10.1186/s13046-019-1259-z; Le D.T., Uram J.N., Wang H., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509–2520. doi:10.1056/NEJMoa1500596; Maio M., Ascierto P.A., Manzyuk L., et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol 2022;33(9):929–938. doi:10.1016/j.annonc.2022.05.519; Andre T., Amonkar M., Norquist J.M., et al. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(5):665–677. doi:10.1016/S1470-2045(21)00064-4; Lenz H.J., Van Cutsem E., Limon M.L., et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: The phase II CheckMate 142 study. J Clin Oncol 2022;40(2):161–170. doi:10.1200/JCO.21.01015; Chalabi M., Fanchi L.F., Dijkstra K.K., et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020;26(4):566–576. doi:10.1038/s41591-020-0805-8; Chalabi M., Verschoor Y.L., van den Berg J., et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Ann Oncol 2022;33(7):S1389. doi:10.1016/j.annonc.2022.08.016; Yuki S., Bando H., Tsukada Y., et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J Clin Oncol 2020;38(15):suppl. 4100. doi:10.1200/JCO.2020.38.15_suppl.4100; Rahma O.E., Yothers G., Hong T.S., et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial [published correction appears in JAMA Oncol 2022 Jul 1;8(7):1073. JAMA Oncol 2021;7(8):1225–1230. doiorg/10.1001/jamaoncol.2021.1683; Ludford K., Ho W.J., Thomas J.V., et al. Neoadjuvant pembrolizumab in localized microsatellite instability high/deficient mismatch repair solid tumors. J Clin Oncol 2023;41(12):2181–2190. doi:10.1200/JCO.22.01351; Cercek A., Lumish M., Sinopoli J., et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 2022;386(25):2363–2376. doi:10.1056/NEJMoa2201445; Tjulandin S., Demidov L., Moiseyenko V., et al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer 2021;149:222–232. doi:10.1016/j.ejca.2021.02.030; Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330–337. doi:10.1038/nature11252; Сунь Х., Неред С.Н., Трякин А.А. и соавт. Прогностическая значимость микросателлитной нестабильности у больных раком желудка, получающих неоадъювантную терапию. Вопросы онкологии 2023;69(2):275–284. doi:10.37469/0507-3758-2023-69-2-275-284.; Tougeron D., Mouillet G., Trouilloud I., et al. Efficacy of adjuvant chemotherapy in colon cancer with microsatellite iInstability: a large multicenter AGEO study. J Natl Cancer Inst 2016;108(7). doi:10.1093/jnci/djv438; Sargent D.J., Marsoni S., Monges G., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer [published correction appears in J Clin Oncol. 2010 Oct 20;28(30):4664. J Clin Oncol 2010;28(20):3219–3226. doi:10.1200/JCO.2009.27.1825; Chakrabarti S., Grewal U.S., Vora K.B., et al. Outcome of patients with early-stage mismatch repair deficient colorectal cancer receiving neoadjuvant immunotherapy : a systematic review. JCO Precis Oncol 2023;7:e2300182. doi:10.1200/PO.23.00182; Gelsomino F., Barbolini M., Spallanzani A., et al. The evolving role of microsatellite instability in colorectal cancer : A review. Cancer Treat Rev 2016;51:19–26. doi:10.1016/j.ctrv.2016.10.005; Pastorino A., Catalano F., Zalcberg J.R., Sobrero A. Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios. Eur J Cancer 2024;199:113538. doi:10.1016/j.ejca.2024.113538; Sinicrope F.A., Mahoney M.R., Smyrk T.C., et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013;31(29):3664–3672. doi:10.1200/JCO.2013.48.9591; Luchini C., Bibeau F., Ligtenberg M.J.L., et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden : a systematic review-based approach. Ann Oncol 2019;30(8):1232–1243. doi:10.1093/annonc/mdz116.; https://www.malignanttumors.org/jour/article/view/1327